Document Detail


Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension.
MedLine Citation:
PMID:  15722985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The main cause of acute diverticulitis is the abnormal accumulation of fecal bacteria within the diverticular lumen, leading to a balancing between normal probiotic microflora and pathogenic species; Gram negative Entero-bacteriaceae, mainly Escherichia coli and Proteus spp, are the genders that usually cause the disease-related symptoms, due to their ability to adhere to intestinal mucosa. The intestine is well known as the largest human lymphoepithelial organ and daily produces more antibodies, mainly secretory IgAs, than do all other lymphoid tissues. IgAs have different immune and anti-inflammatory properties. The aim of this study was to verify the efficacy of an oral immunostimulant highly-purified, polymicrobial lysate in the prevention of recurrent attacks of diverticulitis and in the improvement of symptoms.
METHODS: The study was carried out on 83 consecutive patients suffering from recurrent symptomatic acute diverticulitis and with at least 2 attacks in the previous year; patients were randomly assigned to receive (group A) an oral polybacterial lysate suspension or to a no-treatment clinical follow-up as controls (group B).
RESULTS: A total of 76 patients (41 in group A and 35 in group B) terminated the study period. the sums of the scores for symptoms, reported on day schedules, were calculated and examined by means of ANOVA statistical analysis. Statistical differences between group A vs group B were recorded after 1 month (p<0.05) and 3 months (p<0.01) of treatment with the oral polybacterial lysate suspension.
CONCLUSIONS: Our data suggest that the administration of an oral enterovaccine for the prophylaxis of recurrent diverticulitis is effective and well tolerated, probably due to a direct stimulation of IgA-mediated mucosal defences.
Authors:
L Dughera; A M Serra; E Battaglia; D Tibaudi; M Navino; G Emanuelli
Related Documents :
8359165 - Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requ...
12897315 - Vancomycin use in hospitalized pediatric patients.
10423465 - Oral versus intravenous empirical antimicrobial therapy for fever in patients with gran...
19119075 - Methicillin resistant staphylococcus aureus endocarditis in an australian tertiary hosp...
8917255 - Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angiopla...
10201585 - Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-clos...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Minerva gastroenterologica e dietologica     Volume:  50     ISSN:  1121-421X     ISO Abbreviation:  Minerva Gastroenterol Dietol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2005-02-21     Completed Date:  2005-03-11     Revised Date:  2012-06-22    
Medline Journal Info:
Nlm Unique ID:  9109791     Medline TA:  Minerva Gastroenterol Dietol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  149-53     Citation Subset:  IM    
Affiliation:
Digestive Motility and Endoscopy Unit, Department of Clinical Physiopathology, University of Turin, Turin, Italy. luca.dughera@libero.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adjuvants, Immunologic / administration & dosage*
Administration, Oral
Aged
Analysis of Variance
Anti-Infective Agents / administration & dosage,  therapeutic use
Bacteria
Bacterial Vaccines / administration & dosage*
Cell Extracts / administration & dosage*
Chi-Square Distribution
Ciprofloxacin / administration & dosage,  therapeutic use
Colonoscopy
Diverticulitis / diagnosis,  drug therapy,  immunology,  microbiology,  prevention & control*,  therapy
Diverticulitis, Colonic / diagnosis,  drug therapy,  immunology,  microbiology,  prevention & control,  therapy
Female
Follow-Up Studies
Gastrointestinal Agents / administration & dosage,  therapeutic use
Humans
Injections, Intravenous
Intestinal Mucosa / immunology
Male
Middle Aged
Recurrence
Rifamycins / administration & dosage,  therapeutic use
Time Factors
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Anti-Infective Agents; 0/Bacterial Vaccines; 0/Broncho-Vaxom; 0/Cell Extracts; 0/Gastrointestinal Agents; 0/Rifamycins; 85721-33-1/Ciprofloxacin; 88747-56-2/rifaximin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What do heartburn sufferers expect from proton pump inhibitors when prescribed for the first time?
Next Document:  Intestinal permeability assessment before and after ileal pouch-anal anastomosis.